Why is Rizobacter conducting this exchange offer and consent solicitation?

Rizobacter’s exchange offer and consent solicitation form part of its broader liability management and maturity extension efforts. These actions focus on adjusting the profile of existing debt obligations held in the specified note series.

Bioceres unit completes US$42.7M note exchange

Q: How large is the Rizobacter note exchange reported by BIOX?

The exchange relates to approximately US$42.7 million aggregate principal amount of existing notes. This figure reflects multiple series of Rizobacter’s outstanding notes included in the exchange and consent solicitation process.

Q: Which Rizobacter notes are affected by the US$42.7 million exchange?

The transaction covers Series IX Class A Notes, Series IX Class B Notes, Series X Class A Notes, and Series X Class B Notes. These series together account for the approximately US$42.7 million aggregate principal amount involved.

Bioceres Crop Solutions Corp. reports that its subsidiary Rizobacter Argentina S.A. has successfully completed an exchange offer and consent solicitation for several series of its notes.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Bioceres Crop Solutions Corp. reports that its subsidiary Rizobacter Argentina S.A. has successfully completed an exchange offer and consent solicitation for several series of its notes. The transaction covers approximately US$42.7 million aggregate principal amount of existing notes.

Rizobacter obtained the required consents for its Series IX Class A and B Notes and Series X Class A and B Notes, with participation representing about 86% of the total outstanding principal amount. The exchange forms part of Rizobacter’s broader liability management and maturity extension efforts.

Key Figures

Notes exchanged: US$42.7 million aggregate principal Participation level: Approximately 86% of outstanding principal Form type: Form 6-K +1 more

4 metrics

Notes exchanged US$42.7 million aggregate principal Existing Rizobacter notes included in exchange offer

Participation level Approximately 86% of outstanding principal Consents for Series IX and X notes

Form type Form 6-K Report of foreign private issuer for June 2026

Announcement date May 29, 2026 Date Rizobacter announced successful completion

Key Terms

exchange offer and consent solicitation, liability management, maturity extension, Series IX Class A Notes, +1 more

5 terms

liability management financial

"forms part of Rizobacter’s broader liability management and maturity extension efforts"

Liability management is a company’s plan for handling its debts and obligations—such as refinancing, repaying, or reshaping payment terms—to reduce cost and risk. Like reorganizing household bills or refinancing a mortgage to lower monthly payments, it matters to investors because it affects a firm’s cash flow, creditworthiness and the likelihood of meeting obligations, which in turn can influence stock and bond values.

maturity extension financial

"forms part of Rizobacter’s broader liability management and maturity extension efforts"

Series IX Class A Notes financial

"with respect to the Series IX Class A Notes, Series IX Class B Notes"

Series X Class B Notes financial

"Series X Class A Notes, and Series X Class B Notes issued by Rizobacter"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Bioceres Crop Solutions (BIOX) report in its latest Form 6-K?

Bioceres reports that its subsidiary Rizobacter completed an exchange offer and consent solicitation. The transaction involves about US$42.7 million of notes and is part of broader liability management and maturity extension efforts.

How large is the Rizobacter note exchange reported by BIOX?

The exchange relates to approximately US$42.7 million aggregate principal amount of existing notes. This figure reflects multiple series of Rizobacter’s outstanding notes included in the exchange and consent solicitation process.

What participation level did Rizobacter achieve in the exchange offer?

Rizobacter obtained consents and participation representing about 86% of the total outstanding principal amount of the affected notes. This indicates a high level of noteholder engagement in the exchange and consent solicitation.

Which Rizobacter notes are affected by the US$42.7 million exchange?

The transaction covers Series IX Class A Notes, Series IX Class B Notes, Series X Class A Notes, and Series X Class B Notes. These series together account for the approximately US$42.7 million aggregate principal amount involved.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/01/2026 - 10:16 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rules 13a-16 or 15d-16 under

the Securities Exchange Act of 1934

For the month of June 2026

Commission File Number: 001-38836

BIOCERES CROP SOLUTIONS CORP.

(Translation of registrant’s name into English)

Ocampo 210 bis, Predio CCT, Rosario

Province of Santa Fe, Argentina

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

EXPLANATORY NOTE

This Form 6-K is incorporated by reference into the Company’s registration statements on Form F-3 (Registration No. 333-284195) and Form S-8 (Registration Nos. 333-271941 and 333-266333).

Rizobacter Exchange Offer

On May 29, 2026, Rizobacter Argentina S.A. (“Rizobacter”), a subsidiary of Bioceres Crop Solutions Corp. (the “Company”), announced that Rizobacter has successfully completed an exchange offer and consent solicitation, as the required consents have been obtained with respect to the Series IX Class A Notes, Series IX Class B Notes, Series X Class A Notes, and Series X Class B Notes issued by Rizobacter, with an aggregate participation representing approximately 86% of the total outstanding principal amount thereof.

The transaction relates to approximately US$42.7 million aggregate principal amount of existing notes and forms part of Rizobacter’s broader liability management and maturity extension efforts.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOCERES CROP SOLUTIONS CORP.
	(Registrant)

Dated: June 1, 2026	By:	/s/ Federico Trucco
	Name:	Federico Trucco
	Title:	Chief Executive Officer

Source: View Original Filing on SEC EDGAR